MSD K.K. and Sanofi K.K. announced on February 17 that they have reached an agreement to copromote the pentavalent rotavirus vaccine RotaTeq Oral Solution and the yeast-derived recombinant hepatitis B vaccine Heptavax-II. Both vaccines are manufactured by MSD. Copromotional activities…
To read the full story
Related Article
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
BUSINESS
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
- Sanwa Files Paltusotine in Japan for Acromegaly, Pituitary Gigantism
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





